SILVER SPRING
Idvynso cleared for HIV-1 in adults
- Sponsor
- Merck $MRK
- Drug
- Idvynso · doravirine/islatravir
- Indication
- HIV-1 infection in adults
FDA approved Idvynso, a two-drug single-tablet regimen of doravirine and islatravir, for HIV-1 treatment in adults.
What this means
Idvynso is a once-daily pill combining two HIV drugs that block the virus from multiplying by targeting different stages of its replication process. FDA approved Idvynso for adults with HIV-1, making it the first single-tablet regimen with this specific drug combination. This approval gives patients a simpler treatment option that may reduce the number of pills needed to manage their HIV.
Drug Watch — recent news on Idvynso
- Doravirine Add-On Boosts Virologic Control in HIV Infection - Medscape
- FDA Approves Idvynso Combination Pill - POZ
- Another HIV treatment Option—But With Less Weight Gain - POZ
- Doravirine-based HIV regimen shows less weight gain than dolutegravir combination, trial finds - Managed Healthcare Executive
- Doravirine works as well as dolutegravir to suppress HIV viral load, study finds - Medical Xpress
Sponsor Watch — recent news on Merck
- Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
- The S&P 500 Has Returned About 11% Annually Since 1958. Here's the ETF I'd Trust for the Next 30 Years.
- What Does Merck (MRK) Mean For EU Bladder Cancer Treatment After CHMP Support?
- Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
- 5 Stocks, 5 Different Industries, 1 Thing in Common: Reliable Income